Marko Anderluh

Prof. Marko Anderluh

Prof. and Vice-Dean for Education at University of Ljubljana, Faculty of Pharmacy
+1
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Cellular Signalling
Verified
Journal Article
Closed access
UŠUrban Švajger
Urban Švajger
MAMarko Anderluh
Marko Anderluh
MJMatjaž Jeras
Matjaž Jeras
NONataša Obermajer
Nataša Obermajer

1 July 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
AŠAndrija Šmelcerović
Andrija Šmelcerović
KTKatarina Tomović
Katarina Tomović
ŽŠŽaklina Šmelcerović
Žaklina Šmelcerović
ŽPŽivomir Petronijević
Živomir Petronijević
Gordana KocicGordana Kocic
Gordana Kocic
MAMarko Anderluh
Marko Anderluh

28 May 2018 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
KTKatarina Tomovic
Katarina Tomovic
JLJelena Lazarevic
Jelena Lazarevic
Gordana KocicGordana Kocic
Gordana Kocic
MDMarina Deljanin‐Ilic
Marina Deljanin‐Ilic
MAMarko Anderluh
Marko Anderluh
AŠAndrija Šmelcerović
Andrija Šmelcerović

26 January 2010 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
TTTihomir Tomašić
Tihomir Tomašić
NZNace Zidar
Nace Zidar
AKAndreja Kovač
Andreja Kovač
STSamo Turk
Samo Turk
MSMihael Simčič
Mihael Simčič
Lucija Peterlin MasicLucija Peterlin Masic
Lucija Peterlin Masic

19 October 2016 in eLife
Verified
Journal Article
Open access
NSNitin H Shirole
Nitin H Shirole
DPDEBJANI PAL
DEBJANI PAL
EKEdward R Kastenhuber
Edward R Kastenhuber
SSSerif Senturk
Serif Senturk
JBJoseph Boroda
Joseph Boroda
RSRaffaella Sordella
Raffaella Sordella
TP53 truncating mutations are common in human tumors and are thought to give rise to p53-null alleles. Here, we show that TP53 exon-6 truncating mutations occur at higher than expected frequencies and produce proteins that lack canonical p53 tumor suppressor activities but promote cancer cell proliferation, survival, and metastasis. Functionally and molecularly, these p53 mutants resemble the naturally occurring alternative p53 splice variant, p53-psi. Accordingly, these mutants can localize to the mitochondria where they promote tumor phenotypes by binding and activating the mitochondria inner pore permeability regulator, Cyclophilin D (CypD). Together, our studies reveal that TP53 exon-6 truncating mutations, contrary to current beliefs, act beyond p53 loss to promote tumorigenesis, and could inform the development of strategies to target cancers driven by these prevalent mutations.

1 November 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
MAMarko Anderluh
Marko Anderluh
Gordana KocicGordana Kocic
Gordana Kocic
KTKatarina Tomovic
Katarina Tomovic
RKRadivoj Kocic
Radivoj Kocic
MDMarina Deljanin-Ilic
Marina Deljanin-Ilic
ASAndrija Smelcerovic
Andrija Smelcerovic